Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peripheral inflammation mediates midbrain Lrrk2 kinase activity via Rab32 expression.

bioRxiv : the preprint server for biology·2026
Same author

Vps35 p. D620N causes Lrrk2 kinase hyperactivity, chronic microglial activation and inflammation.

bioRxiv : the preprint server for biology·2026
Same author

How to discover novel genes that cause Parkinson's disease.

Current opinion in neurobiology·2026
Same author

Complementarity of Long-Reads and Optical Mapping in Parkinson's Disease for Structural Variants.

Annals of clinical and translational neurology·2026
Same author

Genetic testing for SCA27B in Korean multiple system atrophy.

Brain : a journal of neurology·2025
Same author

Clinical Features of Families with a Novel Pathogenic Mutation in Sepiapterin Reductase.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Jun 13, 2026

Assaying the Kinase Activity of LRRK2 in vitro
06:09

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

LRRK2 and Parkinson disease.

Justus C Dächsel1, Matthew J Farrer

  • 1Laboratories of Neurogenetics, Department of Neuroscience, Morris K. Udall Parkinson's Disease Research Center of Excellence, Mayo Clinic, Jacksonville, Florida 32224, USA.

Archives of Neurology
|May 12, 2010
PubMed
Summary

Genetic insights into leucine-rich repeat kinase 2 (LRRK2) offer new therapeutic avenues for Parkinson disease (PD). Studying LRRK2 carriers helps define PD

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Leucine-rich repeat kinase 2 (LRRK2) is implicated in parkinsonism.
  • Genetic mutations in LRRK2 are linked to Parkinson disease (PD).

Purpose of the Study:

  • To review the molecular genetics and functional biology of LRRK2 in parkinsonism.
  • To summarize opportunities and challenges for developing PD interventions based on LRRK2 genetics.

Main Methods:

  • Focused on LRRK2 biology literature from 2004 to March 2009.
  • Selected original contributions, seminal observations, and thoughtful reviews.
  • Abstracted data primarily from PubMed.

Main Results:

  • LRRK2 mutations are diagnostically useful in early or atypical PD presentations.

More Related Videos

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag
08:55

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag

Published on: December 14, 2017

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
12:49

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

Related Experiment Videos

Last Updated: Jun 13, 2026

Assaying the Kinase Activity of LRRK2 in vitro
06:09

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag
08:55

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag

Published on: December 14, 2017

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
12:49

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

  • Identified molecular pathways suggest therapeutic interventions for LRRK2 and idiopathic PD.
  • Opportunities exist to develop relevant biomarkers and experimental models.
  • Conclusions:

    • LRRK2 carriers (affected and asymptomatic) enable defining PD's natural history.
    • This includes frequency, penetrance, and progression of motor and non-motor symptoms.
    • Associated biomarkers can also be studied in LRRK2 carriers.